ReviewSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2025
Hepatotoxicity across CDK 4/6 inhibitors: a Narrative Review.
Review in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study.Scientific reports · 2026Article
- CDK4/6 inhibition with dual immunotherapy in chemorefractory SMARCA4-deficient undifferentiated tumor: a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCyclin-dependent kinase 4/6 (CDK4/6) inhibitors have become key agents in the treatment of hormone receptor positive (HR +), human epidermal factor receptor 2 negative (HER2-) metastatic breast cancer (MBC). In combination with endocrine therapy, CDK4/6 inhibitors are currently considered first-line treatment for HR + /HER2- MBC. There are three CDK4/6 inhibitors currently available: palbociclib, ribociclib and abemaciclib. The toxicity profiles of the CDK4/6 inhibitors are well-detailed in the respective clinical trials and post-marketing reports. This review will detail the hepatotoxic effects of CDK 4/6 inhibitors and how the incidence rate compares among agents.
objectiveThis narrative review will fulfill the following objectives: 1. Record and analyze the rates of palbociclib, ribociclib and abemaciclib induced hepatotoxicity in HR + /HER2- breast cancer patients in the literature. 2. Compare the incidences of hepatotoxicity between ribociclib, abemaciclib and palbociclib. 3. Summarize findings and outline future directions in research. SOURCE OF EVIDENCE: Databases (PubMed, Embase) were searched on January 24, 2024.
resultsEvaluating the systematic reviews and meta-analyses included in the narrative review, ribociclib showed the highest risk for all-grade (AG) and grade ≥ 3 (G3 +) alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) elevation. Additionally, ribociclib showed the highest incidence rate of AG and G3 + ALAT/ASAT elevation across its respective randomized clinical trials (RCTs) and pooled safety analysis. Palbociclib showed the highest incidence rate of AG ALAT/ASAT elevation in its respective RCTs and pooled safety analysis. However, palbociclib showed the lowest risk for both AG and G3 + ALAT/ASAT elevation.
conclusionTwenty-five systematic reviews and meta-analyses, RCTs, pooled safety analysis and observational studies were included in this narrative review to evaluate the incidence rate of palbociclib, ribociclib and abemaciclib induced hepatoxicity. Ribociclib seems to be associated with the highest risk of drug-induced hepatotoxicity. More studies need to be done to confirm and quantify this finding.
Indexed as
Identifiers
40524077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.